The Medicines Co.
www.themedicinescompany.com
Latest From The Medicines Co.
New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
The addressable patient population in the US could increase by 4.5 million if new trial is successful.
Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.
Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts
Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.
Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cardiovascular
- Infectious & Viral Diseases
- Inflammation
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- The Medicines Co.
- Senior Management
-
Mark Timney, CEO
Chris Visioli, CFO - Contact Info
-
The Medicines Co.
Phone: (973) 290-6000
8 Sylvan Way
Parsippany, NJ 07054
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice